GLAXO.NS Balance Sheet
Glaxosmithkline Pharmaceuticals Ltd.
Profit & Loss Balance Sheet Cash Flow
Balance Sheet · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-24 01:36
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Property, Plant and Equipment | ₹2.95 Bn | ₹2.97 Bn | ₹2.70 Bn | ₹2.74 Bn | PropertyPlantAndEquipment |
| Capital Work-in-Progress | ₹0.20 Bn | ₹0.14 Bn | ₹0.14 Bn | ₹0.33 Bn | CapitalWorkInProgress |
| Goodwill | ₹0.00 Bn | ₹0.00 Bn | ₹0.00 Bn | ₹0.00 Bn | Goodwill |
| Other Intangible Assets | ₹0.34 Bn | ₹0.24 Bn | ₹0.13 Bn | ₹0.07 Bn | OtherIntangibleAssets |
| Non-current Investments | ₹0.00 Bn | ₹0.00 Bn | ₹0.00 Bn | ₹0.00 Bn | NoncurrentInvestments |
| Other Non-current Assets | ₹0.52 Bn | ₹0.53 Bn | ₹0.52 Bn | ₹0.77 Bn | OtherNoncurrentAssets |
| Total Non-current Assets | ₹6.18 Bn | ₹5.45 Bn | ₹5.02 Bn | ₹5.39 Bn | NoncurrentAssets |
| Inventories | ₹4.60 Bn | ₹5.25 Bn | ₹4.82 Bn | ₹4.58 Bn | Inventories |
| Trade Receivables | ₹1.92 Bn | ₹2.22 Bn | ₹2.93 Bn | ₹2.73 Bn | TradeReceivablesCurrent |
| Cash and Cash Equivalents | ₹0.35 Bn | ₹0.64 Bn | ₹5.39 Bn | ₹11.02 Bn | CashAndCashEquivalents |
| Current Investments | ₹5.18 Bn | ₹8.13 Bn | ₹11.18 Bn | ₹13.91 Bn | CurrentInvestments |
| Other Current Assets | ₹0.30 Bn | ₹0.45 Bn | ₹0.43 Bn | ₹0.54 Bn | OtherCurrentAssets |
| Total Current Assets | ₹27.08 Bn | ₹30.12 Bn | ₹36.06 Bn | ₹37.85 Bn | CurrentAssets |
| Total Assets | ₹33.27 Bn | ₹35.57 Bn | ₹41.08 Bn | ₹43.24 Bn | Assets |
| Equity Share Capital | ₹1.69 Bn | ₹1.69 Bn | ₹1.69 Bn | ₹1.69 Bn | EquityShareCapital |
| Other Equity | ₹15.72 Bn | ₹16.08 Bn | ₹17.82 Bn | ₹20.98 Bn | OtherEquity |
| Equity Attributable to Owners | ₹17.41 Bn | ₹17.78 Bn | ₹19.51 Bn | ₹22.67 Bn | EquityAttributableToOwnersOfParent |
| Non-controlling Interests | ₹0.00 Bn | ₹0.00 Bn | ₹0.00 Bn | ₹0.17 Bn | NonControllingInterest |
| Total Equity | ₹17.41 Bn | ₹17.78 Bn | ₹19.51 Bn | ₹22.85 Bn | Equity |
| Long-term Borrowings | ₹0.00 Bn | ₹0.00 Bn | ₹0.00 Bn | ₹0.00 Bn | BorrowingsNoncurrent |
| Total Non-current Liabilities | ₹2.59 Bn | ₹2.54 Bn | ₹2.52 Bn | ₹2.60 Bn | NoncurrentLiabilities |
| Short-term Borrowings | ₹0.00 Bn | ₹0.00 Bn | ₹0.00 Bn | ₹0.00 Bn | BorrowingsCurrent |
| Trade Payables | ₹4.28 Bn | ₹6.25 Bn | ₹7.08 Bn | ₹5.70 Bn | TradePayablesCurrent |
| Other Current Liabilities | ₹0.56 Bn | ₹0.53 Bn | ₹0.71 Bn | ₹1.18 Bn | OtherCurrentLiabilities |
| Total Current Liabilities | ₹13.26 Bn | ₹15.25 Bn | ₹19.05 Bn | ₹17.79 Bn | CurrentLiabilities |
| Total Equity and Liabilities | ₹33.27 Bn | ₹35.57 Bn | ₹41.08 Bn | ₹43.24 Bn | EquityAndLiabilities |
Every figure above is the exact value of the named XBRL element from GLAXO.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).